MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Stock List・Champions Oncology Inc

C
Champions Oncology Inc

Closed

SectorHealthcare

6.69 3.4

Buy Sell

Overview

Share price change

24h

Current

Min

6.47

Max

6.72

Key metrics
By Trading Economics
Income	702K 236K
Sales	1M 15M
P/E Sector Avg	40.588 88.032
Profit margin	1.57
Employees	213
EBITDA	1.1M 612K

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+83.21% upside

Market Stats
By TradingEconomics
Market Cap	-12M 96M
Previous open	3.29
Previous close	6.69

News Sentiment

By Acuity

35%

65%

112 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

5.77 / 7.61 Support & Resistance

Champions Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

31 Dec 2025, 22:20 UTC

Major Market Movers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 Dec 2025, 17:31 UTC

Major Market Movers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 Dec 2025, 16:30 UTC

Major Market Movers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 Dec 2025, 15:19 UTC

Major Market Movers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 Dec 2025, 15:17 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 Dec 2025, 14:37 UTC

Major Market Movers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 Dec 2025, 21:13 UTC

Acquisitions, Mergers, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 Dec 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 Dec 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 Dec 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 Dec 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31 Dec 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31 Dec 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 Dec 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 Dec 2025, 17:16 UTC

Major Market Movers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 Dec 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31 Dec 2025, 17:00 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 Dec 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 Dec 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 Dec 2025, 15:02 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 Dec 2025, 14:40 UTC

Acquisitions, Mergers, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 Dec 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31 Dec 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 Dec 2025, 13:01 UTC

Earnings

Acquisitions, Mergers, Takeovers

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 Dec 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 Dec 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31 Dec 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 Dec 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 Dec 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer Comparison

Price change

Champions Oncology Inc Forecast

Price Target

By TipRanks

83.21% upside

12 Months Forecast

Average 12 USD 83.21%

High 12 USD

Low 12 USD

Based on 1 Wall Street analysts offering 12 month price targets forChampions Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Champions Oncology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.77 / 7.61Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

112 / 374 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.